RESULTS OF A PROSPECTIVE MULTICENTER OPEN-LABEL OBSERVATIONAL STUDY OF ENZYME REPLACEMENT THERAPY WITH AN IMIGLUCERASE BIOSIMILAR IN CHILDREN WITH TYPE 1 GAUCHER DISEASE
Enzyme replacement therapy (ERT) is the mainstay for type 1 Gaucher disease (GD1) treatment. Imiglucerase biosimilar usage allows to control GD1 manifestations and improve the patients’ life quality according to interventional clinical studies. Objective: To evaluate the results of Glurazyme® use during long-term ERT i...